William Fitzsimmons

Pharmaceutical, organ transplant, pharmacist, COVID-19

[William Fitzsimmons @PharmaFitz]

On this Juneteenth holiday, we @CARER highlight the ongoing need for equitable representation in clinical trials.  New drugs are being approved with poor demographic representation particularly for Black race.  WE can and must do better!

[William Fitzsimmons @PharmaFitz]

The findings from this report suggest that nonprofit pharmaceutical companies have the potential to address drug shortages and enhance access to affordable and essential medicines. https://t.co/4ES9Xy56SA

[William Fitzsimmons @PharmaFitz]

https://t.co/JlbwcA2EIn #transplant

[William Fitzsimmons @PharmaFitz]

I’m headed to #ATC2024Philly to present and share insights on Safety endpoints-a linchpin to Benefit Risk in Kidney Transplantation. See you there!

[William Fitzsimmons @PharmaFitz]

30 years ago today, Prograf (tacrolimus) was approved by FDA. Still used in over 90% of transplants. #transplant #Prograf #tacrolimus

[William Fitzsimmons @PharmaFitz]

House Energy and Commerce Democratic Leaders urge FDA to advance clinical trial diversity efforts
https://t.co/D4MiuTnJ3R
#Diversity #clinicaltrials

[William Fitzsimmons @PharmaFitz]

These data are a call to action-Let's move the needle on clinical trial diversity #FDA #Diversity #DiversityandInclusion #clinicaltrials #clinicalresearch

[STAT @statnews]

Drugs are still mostly tested in white men. Will the FDA change that next year? https://t.co/hiZTXfNZmk

[Jeff Wojtowicz @jwojo4]

Good news about red wine.
https://t.co/tX2sAAxV1R

#wine #winelover #redwine #Redwineandhealth #wineandhealth #wineOclock #Winetime

[William Fitzsimmons @PharmaFitz]

The OPTN data is a key resource for kidney transplant that can be leveraged for supplemental external controls groups. Let's use a surrogate endpoint, e.g. iBOX and use this approach for long term f/u #kidneytransplant https://t.co/nLbtxfWINn

[William Fitzsimmons @PharmaFitz]

New systematic review of effects of moderate red wine consumption on health outcomes. 0/74 studies with negative outcomes
Wojtowicz J S (October 10, 2023) Long-Term Health Outcomes of Regular, Moderate Red Wine Consumption. Cureus 15(10): e46786. doi:10.7759/cureus.46786
#wine

[William Fitzsimmons @PharmaFitz]

Advancing new endpoints in kidney transplantation to accelerate innovation in immunosuppression
https://t.co/gSPvsaKGV6
https://t.co/HFRpWNYenc
#TTC #Kidneytransplant #transplantation #endpoints

[William Fitzsimmons @PharmaFitz]

Real world evidence of immunosuppression and outcomes in pediatric lung transplant. A true ultra orphan indication with 18-50 pediatric lung transplants annually in the US over the last 5 years. #pediatrics #lungtransplant #immunosuppression #rwe
https://t.co/709UYinPUl

[William Fitzsimmons @PharmaFitz]

CARER diversity scorecard for Miebo, an new ophthalmic solution for the treatment of dry eye disease.   The Phase 3 trials included representation from all groups at or above the US population percent.  Kudos to Bausch and Lomb.
#Bausch+lomb #Diversity #Miebo #clinicaltrials

[William Fitzsimmons @PharmaFitz]

CARER group diversity scorecard for the novel new drug Veozah, indicated for hot flashes associated with menopause. The trial population was well represented for Black and Hispanic women however the Asian representation was quite low. #Veozah #clinicaltrials #Diversity

[William Fitzsimmons @PharmaFitz]

Time to innovate in kidney transplant immunosuppression with new endpoints!
https://t.co/817FCH5bVW
#TransplantJrnl #kidneytransplant

[William Fitzsimmons @PharmaFitz]

Qalsody from Biogen, an important novel therapy for ALS. CARER group evaluated the diversity in the pivotal trial. ALS is increased in the elderly; incidence peaks at 70-74 yo; only 9 participants >/=65 yo who received Qalsody. #qalsody #Biogen #Diversity

[William Fitzsimmons @PharmaFitz]

@statnews We need to move the needle on diversity in clinical trials! CARER group developed a diversity scorecard to quantify and grade diversity in new drug approvals.
https://t.co/aOhJjAv4DH

[Samira S. Farouk, MD, MSCR @ssfarouk]

"The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?"

https://t.co/ZqcSoQHz8l

@akdhjournal @ThepHunClub #Transplant #KidneyTransplant

[William Fitzsimmons @PharmaFitz]

The CARER group has developed a new clinical trial diversity scorecard. Our first manuscript summarizing the scorecards for all novel drugs and biologics approved by the FDA from Jan 2022-Feb 2023 is now posted. #FDA #clinicaltrials #Diversity
https://t.co/oRch2zM13I